Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center For Human Genetics And Laboratory Diagnostics, |
RCV000515670 | SCV000611779 | likely pathogenic | Dilated cardiomyopathy 1G | 2017-08-09 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000695044 | SCV000823519 | pathogenic | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2022-02-04 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This sequence change creates a premature translational stop signal (p.Tyr21337*) in the TTN gene. While this is not anticipated to result in nonsense mediated decay, it is expected to create a truncated TTN protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with clinical features of TTN-related conditions (PMID: 31737537; Invitae). ClinVar contains an entry for this variant (Variation ID: 446427). This variant is located in the A band of TTN (PMID: 25589632). Truncating variants in this region are significantly overrepresented in patients affected with dilated cardiomyopathy (PMID: 25589632). Truncating variants in this region have also been reported in individuals affected with autosomal recessive centronuclear myopathy (PMID: 23975875). |
Ambry Genetics | RCV002350135 | SCV002619177 | likely pathogenic | Cardiovascular phenotype | 2021-12-09 | criteria provided, single submitter | clinical testing | The p.Y12272* variant (also known as c.36816C>A), located in coding exon 134 of the TTN gene, results from a C to A substitution at nucleotide position 36816. This changes the amino acid from a tyrosine to a stop codon within coding exon 134. This exon is located in the A-band region of the N2-B isoform of the titin protein and is constitutively expressed in TTN transcripts (percent spliced in or PSI 100%). This variant was reported in an individual with suspected dilated cardiomyopathy (DCM); however, clinical details were not provided (Marschall C et al. Cardiovasc Diagn Ther, 2019 Oct;9:S292-S298). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. While truncating variants in TTN are present in 1-3% of the general population, truncating variants in the A-band are the most common cause of dilated cardiomyopathy (DCM) (Herman DS et al. N. Engl. J. Med., 2012 Feb;366:619-28; Roberts AM et al. Sci Transl Med, 2015 Jan;7:270ra6). TTN truncating variants encoded in constitutive exons (PSI >90%) have been found to be significantly associated with DCM regardless of their position in titin (Schafer S et al. Nat. Genet., 2017 01;49:46-53). As such, this alteration is classified as likely pathogenic. |